Figure 2
From: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Insertion of GGGS removes ADCC activity completely. The ADCC activities of the different PD-L1 antibodies were measured by an in vitro cell killing assay using PD-L1-overexpressed Raji cells together with CD16a (158Â V)-overexpressed NK92MI cells in the presence or absence of PD-L1 antibodies. The line with triangles represents the IMM25 (ADCC- enhanced anti-PD-L1 antibody), the line with squares represents the Maxatezo, (anti-PD-L1 antibody with GGGS insertion), the line with solid circles represents the Atezolizumab (anti-PD-L1 antibody with N297A). The horizontal coordinate is antibody concentration and the vertical coordinate is the percentage of ADCC induced cell lysis.
